why choose us

First received: August 17, 2022

Clinical Trial: HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Prostate Cancer Metastatic

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants With Metastatic Castration-Resistant Prostate Cancer

Brief Summary: This is a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating 2-vector therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a Phase 1 Dose Escalation and recommended Phase 2 dose (RP2D) Confirmation, and a Phase 2 Dose Expansion.

Read more